Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Raquel T Yokoda"'
Autor:
Meenakshi Vij, Benjamin B. Cho, Raquel T. Yokoda, Omid Rashidipour, Melissa Umphlett, Timothy E. Richardson, Nadejda M. Tsankova
Publikováno v:
Acta Neuropathologica Communications, Vol 11, Iss 1, Pp 1-9 (2023)
Abstract Molecular characterization of gliomas has uncovered genomic signatures with significant impact on tumor diagnosis and prognostication. CDKN2A is a tumor suppressor gene involved in cell cycle control. Homozygous deletion of the CDKN2A/B locu
Externí odkaz:
https://doaj.org/article/c577778d01c944589b9ed8e594c91f0b
Autor:
Meenakshi Vij, Raquel T Yokoda, Omid Rashidipour, Ivy Tran, Varshini Vasudevaraja, Matija Snuderl, Raymund L Yong, William S Cobb, Melissa Umphlett, Jamie M Walker, Nadejda M Tsankova, Timothy E Richardson
Publikováno v:
Neuro-Oncology Advances.
Background IDH mutations are thought to represent an early oncogenic event in glioma evolution, found with high penetrance across tumor cells, however in rare cases IDH mutation may exist only in a small subset of the total tumor cells (subclonal IDH
Publikováno v:
Biomedicines, Vol 6, Iss 1, p 33 (2018)
Gastrointestinal malignancies are challenging cancers with considerable economic and societal impacts on health care systems worldwide. While advances in surgical approaches have provided benefits to a proportion of patients, only modest improvements
Externí odkaz:
https://doaj.org/article/a573e95e835a44f7a190d892c755eed4
Autor:
Raquel T. Yokoda, Elizabeth J. Carey
Publikováno v:
American Journal of Gastroenterology. 114:1593-1605
Cholestatic liver diseases encompass a broad spectrum of pathologies, with the core injury occurring at the level of cholangiocytes and progressing to hepatic fibrosis and liver dysfunction. Primary biliary cholangitis and primary sclerosing cholangi
Autor:
Roger A. Fecher, Wendy Szymczak, Erika P. Orner, D. Yitzchak Goldstein, Karin A. Skalina, Inessa Gendlina, Raquel T. Yokoda, Amy S. Fox, Momka Narlieva
Publikováno v:
Journal of Clinical Microbiology
The ability to detect SARS-CoV-2 in the upper respiratory tract ceases after 2 to 3 weeks post-symptom-onset in most patients. In contrast, SARS-CoV-2 can be detected in the stool of some patients for greater than 4 weeks, suggesting that stool may h
Autor:
Raquel T. Yokoda, Eduardo A. Rodriguez
Publikováno v:
World Journal of Hepatology
Cholestatic liver diseases (CLD) begin to develop after an impairment of bile flow start to affect the biliary tree. Cholangiocytes actively participate in the liver response to injury and repair and the intensity of this reaction is a determinant fa
Autor:
Mitesh J. Borad, Raquel T. Yokoda, James M Bogenberger, Jan B. Egan, Daniel H. Ahn, Mansi Arora, Yumei Zhou, Thomas DeLeon, Bolni Marius Nagalo
Publikováno v:
Oncolytic Virotherapy
Upper gastrointestinal tract malignancies are among the most challenging cancers with regard to response to treatment and prognosis. Cancers of the esophagus, stomach, pancreas, liver, and biliary tree have dismal 5-year survival, and very modest imp
Publikováno v:
Case Reports in Hepatology, Vol 2019 (2019)
Case Reports in Hepatology
Case Reports in Hepatology
Drug induced liver injury is a very frequent cause of hepatotoxicity and within that group, herbal and dietary supplements are a well described subcategory. The following clinical vignette describes the case of a young man with acute hepatitis second
Autor:
Hassan Albadawi, Bolni Marius Nagalo, Mitesh J. Borad, Brent Vernon, Jan B. Egan, Yumei Zhou, Rahmi Oklu, Raquel T. Yokoda, Thomas DeLeon, Dan G. Duda
Publikováno v:
Oncolytic Virotherapy
With the advancement of a growing number of oncolytic viruses (OVs) to clinical development, drug delivery is becoming an important barrier to overcome for optimal therapeutic benefits. Host immunity, tumor microenvironment and abnormal vascularity c
Autor:
Alan H. Bryce, Adyr A. Moss, Bashar Aqel, Mohamad Bassam Sonbol, Amit K. Mathur, Mitesh J. Borad, Jorge Rakela, Marcela Salomao, Thomas DeLeon, Ahmad H. Ali, Raquel T. Yokoda, David M. Chascsa
Publikováno v:
Journal of gastrointestinal oncology. 9(6)
Background: Patients with solid organ transplants (SOTs) have been excluded from programmed death protein-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitor clinical trials due to concern for allograft rejection. The use of immune checkpoint inhibi